BlackRock Health Sciences Trust II
BMEZ · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.36 | -0.06 | 0.42 | -0.40 |
| FCF Yield | 34.33% | 15.67% | -0.45% | -0.75% |
| EV / EBITDA | 8.13 | 10.20 | -7.37 | 48.43 |
| Quality | ||||
| ROIC | 0.12% | 1.42% | 0.25% | 0.01% |
| Gross Margin | 100.00% | 352.41% | 100.00% | 10.73% |
| Cash Conversion Ratio | 2.79 | 1.60 | 0.03 | -0.36 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -48.41% | – | – |
| Free Cash Flow Growth | 104.63% | 3,763.28% | 95.95% | -11.39% |
| Safety | ||||
| Net Debt / EBITDA | 0.01 | 0.00 | -0.03 | 0.00 |
| Interest Coverage | 11,886.87 | 153,893.45 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 18.13 | 70.24 | -33.29 | 19.44 |